Fbg, correct I did think yesterday's PR would do nothing based on similar previous deals, but I would not lump the Astra deal into that group considering it was with a BP with upfront cash and a stock purchase. Yesterday's contained none of those and reminded me of all the other DO deals. I think it would be a poor management decision to execute a big AXAL deal now at this price compared to after ASCO. With the GOG abstract coming in march, then hoping Dan can carry and build on any momentum going into asco and releasing any great data there, then follow that up with the deal could significantly add SH value in the form of less dilution. That is assuming we are still not in the single digits after asco. We will have much worse things to worry about if that is the case. Dan is big on doing deals based on strength and not weakness so why execute your largest deal to date at our pitiful current valuation. Get the price up, release the data, make the deal, and let the market handle the shorts.
News 
Market Data 
Discover 
